Identification of three predictors of gastric cancer progression and prognosis

FEBS Open Bio. 2020 Sep;10(9):1891-1899. doi: 10.1002/2211-5463.12943. Epub 2020 Aug 18.

Abstract

Abnormal gene expression is an established cause of gastric cancer (GC) initiation and progression. In this study, we aimed to identify several key genes that could be used to effectively predict progression and prognosis in patients with GC. The Cancer Genome Atlas and the Gene Expression Omnibus database were used to identify candidate genes. Fourteen genes were found to associate highly with progress, metastasis, and survival of GC. Five of these genes were overexpressed in tumor tissue compared to adjacent normal tissue. This was confirmed by reverse transcription-polymerase chain reaction and western blotting for myosin-Va (MYO5A), phospholipid transfer protein (PLTP), and tripeptidyl peptidase 1 (TPP1), while the CCK8 assay was used to show that these three genes promote GC cell proliferation. In summary, we demonstrate that MYO5A, PLTP, and TPP1 expression may be suitable markers for the progression and prognosis of GC.

Keywords: GEO; TCGA; gastric cancer; potential predictors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aminopeptidases / genetics*
  • Biomarkers, Tumor / genetics*
  • Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / genetics*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myosin Heavy Chains / genetics*
  • Myosin Type V / genetics*
  • Phospholipid Transfer Proteins / genetics*
  • Serine Proteases / genetics*
  • Stomach Neoplasms / diagnosis
  • Stomach Neoplasms / genetics*
  • Tripeptidyl-Peptidase 1
  • Tumor Cells, Cultured

Substances

  • Biomarkers, Tumor
  • PLTP protein, human
  • Phospholipid Transfer Proteins
  • Tripeptidyl-Peptidase 1
  • MYO5A protein, human
  • Serine Proteases
  • Aminopeptidases
  • Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
  • TPP1 protein, human
  • Myosin Type V
  • Myosin Heavy Chains